$46.38 1.13 (+2.50%)
11/25/2009 4:01 PM

AstraZeneca plc (ADR) (AZN)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Results 1 - 11 of 11

Recs

0
Member Avatar shinier (42.70) Submitted: 9/4/2009 2:52:54 PM : Underperform Start Price: $45.35 AZN Score: +7.51

Looks like a recession stock, and we could be headed out of that sooner than later.

Recs

0
Member Avatar knblizzard (31.93) Submitted: 6/2/2009 1:07:16 PM : Underperform Start Price: $41.09 AZN Score: +6.12

This is a great stock, it will gain with it working with other companies, but it will not out pace the S&P. This is going to be a steady stock with few huge gains.

Recs

0
Member Avatar Macademia (92.31) Submitted: 1/10/2009 1:44:08 PM : Underperform Start Price: $38.70 AZN Score: +7.75

Oncology is a major area for any pharmaceutical company. Arimidex is about to go off patent in the next two years and they have no other blockbusters that are far along in clinical trial development.

Recs

1
Member Avatar KingPortu (30.23) Submitted: 10/29/2007 2:34:48 PM : Underperform Start Price: $44.11 AZN Score: -29.30

I like the MedImmune acquisition but their balance sheet looks like crap- 5billion in cash vs 15billion in debt, plus negative earnings and revenue. Think it will take some time before the MedImmune acquisition starts to pay off

Recs

0
Member Avatar mimosapartners (< 20) Submitted: 9/23/2007 2:13:54 PM : Underperform Start Price: $44.92 AZN Score: -26.68

Several state AG's; Arkansas for one, have joined in a class action lawsuit that may prove costly for AZN.

Recs

0
Member Avatar aaroger (26.87) Submitted: 7/25/2007 3:37:52 PM : Underperform Start Price: $49.44 AZN Score: -16.42

65

Recs

0
Member Avatar incansun (76.31) Submitted: 6/14/2007 6:43:14 PM : Underperform Start Price: $46.53 AZN Score: -23.12

This stock is analogous to the titanic. Bad news when CFO leaves right after a big transaction with MedImmune.

Recs

1
Member Avatar marionvb (65.82) Submitted: 4/6/2007 4:50:47 PM : Underperform Start Price: $48.57 AZN Score: -14.09

They may need some Levitra as some of their drugs go off patent.

Recs

1
Member Avatar flexnexus (20.31) Submitted: 3/15/2007 10:46:44 PM : Underperform Start Price: $50.54 AZN Score: -7.23

While AZN has made a smart deal with Palatin (PTN), I'm generally bearish on big pharma. Lots of legislation is going to come about that will cost them a lot of money.

Recs

0
Member Avatar OldNickel (96.46) Submitted: 12/28/2006 11:27:09 PM : Underperform Start Price: $47.21 AZN Score: -15.01

The Democrats are coming! The Democrats are coming!

Recs

0
Member Avatar Rightime (71.88) Submitted: 9/13/2006 6:44:44 AM : Underperform Start Price: $55.01 AZN Score: +5.91

AstraZeneca halted development of two new drug candidates: Galida for diabetes and Exanta for blood clotting. Nexuim may face pressure from prilosec due to cost by insurance companies. Crestor is a good play.

Results 1 - 11 of 11

Featured Broker Partners